Gubra announces achievement of milestone from AbbVie following initiation of a Phase 2 clinical trial of ABBV-295, a long-acting amylin analog

• ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists.
• Under Gubra’s license agreement with AbbVie, the initiation of the Phase 2 trial triggers a milestone payment of USD 50 million to Gubra.

Markus Rohrwild, CEO of Gubra, says:
“The advancement of ABBV-295 into Phase 2 marks an important milestone for Gubra and brings the program another step closer to potentially expanding treatment options for people living with overweight or obesity. The Phase 1 data have demonstrated encouraging potential for differentiation, and we believe ABBV-295 has the potential to become an important part of the next generation of therapies for chronic weight management. We are very pleased to see the program progress into Phase 2 under AbbVie’s leadership. This achievement also provides further validation of the strength of Gubra’s drug discovery platform and our ability to discover and develop differentiated peptide therapeutics with the potential to address major unmet medical needs.”

The Phase 2 trial is a randomized, double-blind, placebo-controlled, dose-finding trial designed to evaluate the efficacy, safety, and tolerability of ABBV-295 in approximately 360 adults who are obese (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Participants will be randomized to one of six active treatment arms or placebo, evaluating different dosing paradigms over a 52-week treatment period. The primary endpoint is the percentage change in body weight from baseline at week 32. Additional details are available at ClinicalTrials.gov (Identifier: NCT07752979).

The Phase 2 initiation of ABBV-295 is supported by data from a comprehensive Phase 1 program, including single ascending dose (SAD) and multiple ascending dose (MAD) studies. The 12/13-week Phase 1 MAD study in adults (88% male) with a mean BMI below 30 kg/m² at baseline demonstrated dose-dependent weight reduction of up to 9.8% with weekly dosing after 12 weeks, with comparable weight reduction observed after 13 weeks with every-other-week and monthly dosing after week 5. ABBV-295 demonstrated a favorable safety and tolerability profile at all evaluated dose levels. An ongoing Phase 1b MAD study in the U.S. (ClinicalTrials.gov ID: NCT07291232) is evaluating ABBV-295 in participants with obesity, with a higher baseline BMI (30–45 kg/m²) and a greater proportion of female participants compared with the prior Phase 1 MAD studies.

About ABBV-295
ABBV-295 is an investigational, long-acting amylin analog being developed for chronic weight management and other potential indications. ABBV-295 was discovered by Gubra using Gubra´s streaMLine platform. ABBV-295 has not been approved by any health regulatory authority worldwide. The safety and efficacy of ABBV-295 have not been established.

About the AbbVie and Gubra partnership
In March 2025, Gubra and AbbVie entered into a license agreement for ABBV-295. Under the terms of the agreement, AbbVie will lead development and commercialization activities of ABBV-295 globally. Gubra is eligible to receive up to USD 1.875 billion in potential development, commercial, and sales-based milestone payments, as well as tiered royalties on global net sales.

Contacts at Gubra
Media: Marianne Thomas ([email protected], +45 2483 2663)
Investors: Kristian Borbos ([email protected], +45 3080 8035) and Adam Lange ([email protected], +45 6646 1589)

About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025.

See www.gubra.dk for more information.

Legal Notices
© 2026 Gubra A/S ("Gubra"). All Gubra logos, trademarks and trade names are the property of Gubra A/S or its affiliates. Any third-party trademarks or tradenames referenced are the property of their respective owners and references do not imply third party endorsement or sponsorship. All rights reserved.

This information is intended solely for corporate communications and investor relations purposes. It does not constitute medical advice, advertising, promotion, or marketing of any product. At date of publication, Gubra’s biotechnology or partnered products are investigational development candidates and have not received a marketing authorization in any country worldwide.

This information is not a prospectus or offering circular and does not constitute investment advice or an offer to buy or sell securities in Denmark or any jurisdiction, including the United States.

The information or opinions provided are made at the date of publication and are subject to change. While reasonable care has been taken, Gubra makes no warranty of accuracy, completeness, or reliability. Information or opinions provided may also include third party data that has not been independently verified.

This document may contain forward‑looking statements involving opportunities, expectations, risks and uncertainties, however actual results may differ materially. The forward-looking statements can be identified by words such as “aim”, “anticipate”, “believe” “could”, “estimate”, “expect”, “forecast” “goal”, “intend”, “may”, “plan”, “possible”, “potential”, “would”, and other words and terms of similar meaning. Investors are cautioned not to rely on these statements and Gubra disclaims and excludes all liability caused by such reliance. We do not undertake or commit to update these statements for subsequent changes, unless required by applicable laws, rules or regulation.